A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
Key facts
- Who runs it
- Pfizer
- Where
- Chicago, Lake Success, Los Angeles, New Hyde Park, and Phoenix, United StatesSee the 5 sitesAlso in 18 other countries, 46 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 100 people enrolled
- Started
- 10 May 2018
- Ended
- 27 Mar 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- In open-label phase: treatment with tofacitinib
- In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
- Record updated
- 3 June 2025
Who can take part
- Age
- 2 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- active sJIA disease according to ILAR criteria before screening and at baseline (Day 1)
- Treatment with stable doses of methotrexate (MTX) ≤25 mg/week or ≤20 mg/m2/week, whichever is lower, is permitted
- Treatment with a stable dose of oral prednisone ≤1 mg/kg/day up to a maximum of 30 mg/day, or equivalent, for at least 1 week before the first study drug dose is permitted
Who cannot take part
- Previous juvenile idiopathic arthritis (JIA) treatment with tofacitinib
- Current infection or serious infection within 3 months of study enrollment
- Current symptoms or findings of myocarditis, endocarditis or more than minimal pericardial effusion associated with systemic juvenile idiopathic arthritis (sJIA). Current symptoms or findings of more than minimal pleuritis with sJIA
Where in United States
Also in 18 other countries, 46 sites
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States
- Cohen Children's Medical Center of New YorkLake Success, United States
- Children's Hospital Los AngelesLos Angeles, United States
- Cohen Children's Medical Center of New YorkNew Hyde Park, United States
- Phoenix Children s HospitalPhoenix, United States
About the trial
What the trial wants to find out
A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. An interim analysis for efficacy and futility will be conducted when at least 20 flares have been observed. If either criterion is met, the study will be stopped. If neither criterion is met, the study will continue until the requisite number of flares are observed as determined by the number of flares included in the interim analysis and a statistical penalty for conducting the interim analysis.
The 2 groups in the trial
- Tofacitinib 5 mg BIDTreatment being tested
oral, twice daily, tablet or solution.
Treatment: In open-label phase: treatment with tofacitinib and In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
- PlaceboPlacebo, for comparison
Treatment: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS
- Record updated
- 3 June 2025